Mary Paine

Prof. Mary Paine

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
SBScott J. Brantley
Scott J. Brantley
AAAneesh A Argikar
Aneesh A Argikar
YLYvonne S. Lin
Yvonne S. Lin
SNSwati Nagar
Swati Nagar
MPMary Paine
Mary Paine
Supported by a usage history that predates written records and the perception that “natural” ensures safety, herbal products have increasingly been incorporated into Western health care. Consumers often self-administer these products concomitantly with conventional medications without informing their health care provider(s). Such herb–drug combinations can produce untoward effects when the herbal product perturbs the activity of drug metabolizing enzymes and/or transporters. Despite increasing recognition of these types of herb–drug interactions, a standard system for interaction prediction and evaluation is nonexistent. Consequently, the mechanisms underlying herb–drug interactions remain an understudied area of pharmacotherapy. Evaluation of herbal product interaction liability is challenging due to variability in herbal product composition, uncertainty of the causative constituents, and often scant knowledge of causative constituent pharmacokinetics. These limitations are confounded further by the varying perspectives concerning herbal product regulation. Systematic evaluation of herbal product drug interaction liability, as is routine for new drugs under development, necessitates identifying individual constituents from herbal products and characterizing the interaction potential of such constituents. Integration of this information into in silico models that estimate the pharmacokinetics of individual constituents should facilitate prospective identification of herb–drug interactions. These concepts are highlighted with the exemplar herbal products milk thistle and resveratrol. Implementation of this methodology should help provide definitive information to both consumers and clinicians about the risk of adding herbal products to conventional pharmacotherapeutic regimens.

25 January 2019 in Natural Product Reports
Verified
Journal Article
Open access
PDF file
JKJoshua Kellogg
Joshua Kellogg
MPMary Paine
Mary Paine
JMJeannine S. McCune
Jeannine S. McCune
NONicholas H. Oberlies
Nicholas H. Oberlies
NCNadja B. Cech
Nadja B. Cech
Covering: up to the end of 2018 Dietary supplements, which include botanical (plant-based) natural products, constitute a multi-billion-dollar industry in the US. Regulation and quality control for this industry is an ongoing challenge. While there is general agreement that rigorous scientific studies are needed to evaluate the safety and efficacy of botanical natural products used by consumers, researchers conducting such studies face a unique set of challenges. Botanical natural products are inherently complex mixtures, with composition that differs depending on myriad factors including variability in genetics, cultivation conditions, and processing methods. Unfortunately, many studies of botanical natural products are carried out with poorly characterized study material, such that the results are irreproducible and difficult to interpret. This review provides recommended approaches for addressing the critical questions that researchers must address prior to in vitro or in vivo (including clinical) evaluation of botanical natural products. We describe selection and authentication of botanical material and identification of key biologically active compounds, and compare state-of-the-art methodologies such as untargeted metabolomics with more traditional targeted methods of characterization. The topics are chosen to be of maximal relevance to researchers, and are reviewed critically with commentary as to which approaches are most practical and useful and what common pitfalls should be avoided.

1 September 2019 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ECEmily J. Cox
Emily J. Cox
NMNeha Maharao
Neha Maharao
GPGabriela Patilea-Vrana
Gabriela Patilea-Vrana
JUJashvant D. Unadkat
Jashvant D. Unadkat
ARAllan E. Rettie
Allan E. Rettie
MPMary Paine
Mary Paine

30 June 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SBSumit Bansal
Sumit Bansal
CZC. Austin Zamarripa
C. Austin Zamarripa
TSTory R. Spindle
Tory R. Spindle
EWElise M. Weerts
Elise M. Weerts
KTKenneth E. Thummel
Kenneth E. Thummel
JUJashvant D Unadkat
Jashvant D Unadkat

11 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RTRakshit Sanjay Tanna
Rakshit Sanjay Tanna
JNJames Nguyen
James Nguyen
DHDeena L. Hadi
Deena L. Hadi
PMPreston Manwill
Preston Manwill
LFLaura Flores-Bocanegra
Laura Flores-Bocanegra
MPMary Paine
Mary Paine
Increasing use of the botanical kratom to self-manage opioid withdrawal and pain has led to increased kratom-linked overdose deaths. Despite these serious safety concerns, rigorous fundamental pharmacokinetic knowledge of kratom in humans remains lacking. We assessed the pharmacokinetics of a single low dose (2 g) of a well-characterized kratom product administered orally to six healthy participants. Median concentration-time profiles for the kratom alkaloids examined were best described by a two-compartment model with central elimination. Pronounced pharmacokinetic differences between alkaloids with the 3S configuration (mitragynine, speciogynine, paynantheine) and alkaloids with the 3R configuration (mitraciliatine, speciociliatine, isopaynantheine) were attributed to differences in apparent intercompartmental distribution clearance, volumes of distribution, and clearance. Based on noncompartmental analysis of individual concentration-time profiles, the 3S alkaloids exhibited a shorter median time to maximum concentration (1–2 vs. 2.5–4.5 h), lower area under the plasma concentration-time curve (430–490 vs. 794–5120 nM × h), longer terminal half-life (24–45 vs. ~12–18 h), and higher apparent volume of distribution during the terminal phase (960–12,700 vs. ~46–130 L) compared to the 3R alkaloids. Follow-up mechanistic in vitro studies suggested differential hepatic/intestinal metabolism, plasma protein binding, blood-to-plasma partitioning, and/or distribution coefficients may explain the pharmacokinetic differences between the two alkaloid types. This first comprehensive pharmacokinetic characterization of kratom alkaloids in humans provides the foundation for further research to establish safety and effectiveness of this emerging botanical product.

2 November 2018 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
DTDan‐Dan Tian
Dan‐Dan Tian
SNSenthil Natesan
Senthil Natesan
JWJohn R. White
John R. White
MPMary Paine
Mary Paine
The caffeine metabolic ratio is an established marker for cytochrome P450 ( CYP ) 1A2 activity. Optimal sample size calculation for clinical pharmacokinetic xenobiotic–caffeine interaction studies requires robust estimates of interindividual and intraindividual variation in this ratio. Compared with interindividual variation, factors contributing to intraindividual variation are less defined. An exploratory analysis involving healthy nonsmoking non‐naïve caffeine drinkers (1–3 cups/day; 12 men, 12 women) administered caffeine (160 mg) on five occasions evaluated the effects of CYP 1A2 induction status (based on genotype) and other factors on intraindividual variation in CYP 1A2 activity. Results were compared with those from previous studies. Regardless of whether a hyperinducer ( CYP 1A2*1A/*1F or CYP 1A2*1F/*1F ) or normal metabolizer ( CYP 1A2*1A/*1A , CYP 1A2*1C/*1F , or CYP 1A2*1C*1F/*1C*1F ), sex, age, oral contraceptive use by women, and smoking status, intraindividual variation was ≤30%. A value of 30% is proposed for optimal design of pharmacokinetic xenobiotic–caffeine interaction studies. Prospective studies are needed for confirmation.